Is COMPASS Pathways plc (CMPS) a Buy, Sell, or Hold?
NASDAQ : CMPS
COMPASS Pathways plc
$12.43 USD
-$0.88 (-6.61%)
- Volume
- 2.5M
- Average Volume
- 4.89M
- Market Capitalization
- $1.19B
- P/E Ratio
- -6.00
- Dividend Yield
- 0.00%
- Price Target
- $20.00
- Year High
- $15.40
- Year Low
- $3.83
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $3.32
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Kabir Kumar Nath |
| Industry | Medical - Care Facilities |
| Sector | Healthcare |
| Current Symbol | CMPS |
| CUSIP | 20451W101 |
| CIK | 0001816590 |
| Web | https://compasspathways.com |
| Phone | 44 64 6905 3974 |
| Currency | USD |
| Employees | 156 |
| Country | GB |
Liquidity
| Debt-to-Equity Ratio | 0.01 |
| Payout Ratio | 0.00 |
| Current Ratio | 3.32 |
| Quick Ratio | 3.32 |
| Cash Ratio | 3.03 |
Sales & Book Value
| Annual Sales | -$ |
| Price / Sales | 0.00 |
| Cash Flow | -1.45 |
| Price / Cash Flow | -7.76 |
| Price / Book | 4.34 |
Price Target and Rating
| Average Stock Price Forecast | $20.00 |
| High Stock Price Forecast | $25.00 |
| Low Stock Price Forecast | $17.00 |
| Forecast Upside/Downside | -37.85% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 14 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | -$3.08 |
| Trailing P/E Ratio | -6.00 |
| PEG Ratio | 0.16 |
| P/E Growth | 0.16 |
| Net Income | -$287.86M |
| Net Margin | 0.00% |
| Pretax Margin | 0.00% |
| Return on Equity | -150.89% |
| Return on Assets | -33.62% |
Financials Score
| AltmanZ Score | 1.55 |
| Piotroski Score | 2.00 |
| Working Capital | 357.07M |
| Total Assets | 531.74M |
| Ebit | -176.84M |
| Market Cap | 1.29B |
| Total Liabilities | 205.05M |
Poll Results
About COMPASS Pathways plc (NASDAQ:CMPS) Stock
COMPASS Pathways plc is a mental healthcare company with a primary presence in the United Kingdom and the United States. Established in 2020 and headquartered in London, UK, the firm focuses on developing novel treatments. Its key product is COMP360, an investigational psilocybin therapy. This therapy has advanced through Phase IIb clinical trials for treatment-resistant depression and is currently undergoing Phase II trials for post-traumatic stress disorder. The company previously operated under the name COMPASS Rx Limited before rebranding to COMPASS Pathways plc in August 2020. ...
2026-07-16 06:35:00
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the publication of a post-hoc analysis of support methods used in an open-label Phase 2 study of investigational COMP360 synthetic psilocybin treatment in patients with post-traumatic stress disorder (PTSD). Documented speech production between participants and support providers during treatment a.
Johnson & Johnson’s Spravato sales growth supports psychedelic drug opportunity: Jefferies
2026-07-15 11:34:00
Psychedelic drug developers including AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC), Compass Pathways (NASDAQ:CMPS) and Cybin Inc. (NYSE-A:CYBN, FRA:R7E) could...
CleanSpark shares surge after company secures $6.6B data center lease agreement
2026-07-14 07:53:00
CleanSpark Inc (NASDAQ:CLSK) shares surged more than 12% after the company announced a 20-year lease agreement for its Sandersville, Georgia data center...
2026-07-14 07:20:00
Tower Semiconductor (NASDAQ:TSEM) shares rose 13% on Tuesday after the company announced a strategic expansion of its silicon photonics, silicon germanium...
Compass Pathways Eyes 2027 Launch as Psilocybin Depression Data Holds Up
2026-07-10 03:03:16
Compass Pathways NASDAQ: CMPS said new 26-week data from its Phase 3 COMP006 trial further support the durability and safety profile of COMP360, its investigational psilocybin therapy for treatment-resistant depression, as the company works toward a potential U.S. launch in the first half of 2027.
Compass Pathways: 'Strong Buy' COMP360 Trial Wins And Q4 NDA Full Submission
2026-07-08 13:23:52
Compass Pathways: 'Strong Buy' COMP360 Trial Wins And Q4 NDA Full Submission
2026-07-07 17:32:28
COMPASS Pathways plc (CMPS) Discusses Six-Month Data from Second Phase 3 Trial Confirming Rapid and Durable Profile in Depression Transcript
Compass Pathways Highlights Long-Term Data from Resistant Depression, Backs 2027 Launch Timeline
2026-07-07 12:24:36
Compass Pathways plc (NASDAQ:CMPS) on Wednesday reported 26-week results from Part B of its Phase 3 COMP006 trial, reinforcing the rapid and durable efficacy of COMP360, its synthetic psilocybin therapy for treatment-resistant depression (TRD).
Frequently Asked Questions
-
What is the current COMPASS Pathways plc (CMPS) stock price?
-
COMPASS Pathways plc(NASDAQ:CMPS) stock price is $12.43 in the last trading session. During the trading session, CMPS stock reached the peak price of $15.4 while $3.83 was the lowest point it dropped to. The percentage change in CMPS stock occurred in the recent session was --6.61% while the dollar amount for the price change in CMPS stock was -$0.88.
-
CMPS's industry and sector of operation?
-
The NASDAQ listed CMPS is part of Medical - Care Facilities industry that operates in the broader Healthcare sector.
-
Who are the executives of CMPS?
-
Guy Goodwin | Chief Medical Officer
Teri Loxam | Chief Financial Officer
Kabir Nath | Chief Executive Officer & Director
Benjamin Harber | Company Secretary
Steve Levine | Chief Patient Officer -
How many employees does CMPS have?
-
Number of CMPS employees currently stands at 156. CMPS operates from 33 Broadwick Street, London, CH W1F 0DQ, GB.
-
Link for CMPS official website?
-
Official Website of CMPS is: https://compasspathways.com
-
How do I contact CMPS?
-
CMPS could be contacted at phone #44 64 6905 3974 and can also be accessed through its website. CMPS operates from 33 Broadwick Street, London, CH W1F 0DQ, GB.
-
How many shares of CMPS are traded daily?
-
The average number of CMPS shares traded daily for last 3 months was 4.89M.
-
What is the market cap of CMPS currently?
-
The market value of CMPS currently stands at $1.19B with its latest stock price at $12.43